ImmunoGen, Inc. (IMGN) Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma  
9/23/2011 10:39:58 AM

WALTHAM, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced its submission of the Investigational New Drug (IND) application for its IMGN529 product candidate to the U.S. Food and Drug Administration (FDA).